Atherosclerotic Cardiovascular Disease
📧 Sign up to get email alerts when something new happens for Atherosclerotic Cardiovascular Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-01-14FDA Approved: ROSUVASTATIN CALCIUM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for rosuvastatin calcium submitted by Sun Pharmaceutical Industries, Inc., approving an additional f…
-
FDA approval · 2025-01-14FDA Approved: ROSUVASTATIN — Supplemental Application (ScieGen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for rosuvastatin submitted by ScieGen Pharmaceuticals, enabling the marketing of a generic rosuv…
-
FDA approval · 2025-01-14FDA Approved: ROSUVASTATIN CALCIUM — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for Rosuvastatin Calcium from Ascend Laboratories, LLC, supporting the continued availability of a r…
-
FDA approval · 2025-01-14FDA Approved: ROSUVASTATIN CALCIUM — Supplemental Application (Umedica Laboratories USA Inc.)
The FDA granted supplemental approval for rosuvastatin calcium under an ANDA for Umedica Laboratories USA Inc., confirming the generic produ…
-
FDA approval · 2025-01-10FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Biocon Pharma Inc.)
FDA approved Biocon Pharma Inc.'s supplemental application for atorvastatin calcium, authorizing its continued marketing as a generic statin…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-12-19FDA Approved: EZETIMIBE AND SIMVASTATIN — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approved a supplemental application for the ezetimibe and simvastatin combination from Amneal Pharmaceuticals NY LLC.
-
FDA approval · 2024-12-17FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for atorvastatin calcium (generic) from Ascend Laboratories, LLC, for this ANDA, approving regulator…
-
CLINICAL_TRIALS research · 2024-12-13Clinical Trial Update: Effect of Icosapent-ethyl Ester (IPE) to Reduce the Residual Risk Cardiovascular Disease. [NA]
This clinical trial update reports that a study evaluating icosapent-ethyl ester (IPE) to reduce residual cardiovascular risk in patients wi…
-
CLINICAL_TRIALS research · 2024-12-12Clinical Trial Update: Variability in Human Fatty Acids Profiles Based on Blood Fractions and Metabolic Conditions [NA]
A clinical trial update investigating how human fatty acid profiles vary across blood fractions and metabolic conditions in individuals with…
-
FDA approval · 2024-12-09FDA Approved: ROSUVASTATIN CALCIUM — Supplemental Application (Quallent Pharmaceuticals Health LLC)
The FDA approved a supplemental application for a generic rosuvastatin calcium product from Quallent Pharmaceuticals Health LLC under ANDA20…
-
FDA approval · 2024-12-05FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for atorvastatin calcium from Mylan Pharmaceuticals Inc., authorizing the continued marketing of the…
-
FDA approval · 2024-12-04FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Sun Pharmaceutical Industries Inc.)
FDA approved a supplemental application for atorvastatin calcium from Sun Pharmaceutical Industries Inc., enabling the generic atorvastatin …
-
FDA approval · 2024-11-27FDA Approved: SIMVASTATIN — Original Application (Westminster Pharmaceuticals, LLC)
FDA approved Westminster Pharmaceuticals' original application for a generic simvastatin product, adding another generic option for choleste…
-
FDA approval · 2024-11-20FDA Approved: REPATHA — Supplemental Application (Amgen USA Inc.)
The FDA approved a supplemental application for Repatha (evolocumab) submitted by Amgen USA Inc.
-
CLINICAL_TRIALS withdrawal · 2024-11-18Clinical Trial Update: Effect of Switching From Cigarette Smoking to THS on Systemic Endothelial Function in Subjects With Established Atherosclerotic Disease [NA]
A clinical trial evaluating the effect of switching from cigarette smoking to the Tobacco Heating System (THS) on systemic endothelial funct…
-
FDA approval · 2024-11-06FDA Approved: ROSUVASTATIN — Original Application (Macleods Pharmaceuticals Limited)
FDA approved the original application for rosuvastatin by Macleods Pharmaceuticals Limited, establishing a generic rosuvastatin product. Thi…
-
FDA approval · 2024-11-04FDA Approved: AMLODIPINE AND ATORVASTATIN — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for the fixed-dose combination of amlodipine and atorvastatin by Prasco Laboratories.
-
FDA approval · 2024-11-04FDA Approved: PITAVASTATIN — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for pitavastatin calcium under ANDA205955. The approval pertains to the generic pitavastatin product…
-
CLINICAL_TRIALS trial_result · 2024-10-23Clinical Trial Update: Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients [Phase 3]
Phase 3 trial evaluating LIB003 in combination with Inclisiran for efficacy and safety in high-risk cardiovascular disease patients has comp…
-
CLINICAL_TRIALS research · 2024-10-22Clinical Trial Update: Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction [Phase 3]
Phase 3 open-label extension evaluating long-term efficacy and safety of LIB003 in patients with homozygous and heterozygous familial hyperc…
-
FDA approval · 2024-10-16FDA Approved: ROSUVASTATIN CALCIUM — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for rosuvastatin calcium from Rising Pharma Holdings, Inc., granting approval for a generic rosu…
-
FDA approval · 2024-10-15FDA Approved: ROSUVASTATIN CALCIUM — Supplemental Application (Glenmark Pharmaceutials Inc., USA)
FDA approved a supplemental application for rosuvastatin calcium from Glenmark Pharmaceuticals, confirming regulatory approval of this gener…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: NPC1L1 Gene Polymorphism and the Efficacy and Safety of Hybutimibe
The document outlines a clinical trial to evaluate the impact of NPC1L1 gene polymorphisms on the efficacy and safety of Hybutimibe in ather…
-
CLINICAL_TRIALS other · 2024-09-24Clinical Trial Update: Relationship of Noninvasive Assessment of Central BP With 10 Years Atherosclerotic CVD in Subclinical Hypothyroidism
A clinical trial update notes a study evaluating the relationship between noninvasively assessed central blood pressure and 10-year risk of …
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE) [Phase 3]
Phase 3 trial comparing an 'Inclisiran First' implementation strategy to usual care in patients with atherosclerotic cardiovascular disease …